Effects of treatment with Pantoprazole on biochemical and vascular function parameters in health volunteers.

• Grant number: 22/06102-9
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Effective date (Start): October 01, 2022
• Effective date (End): August 31, 2023
• Field of knowledge: Biological Sciences - Pharmacology - Clinical Pharmacology
• Principal Investigator: Jose Eduardo Tanus dos Santos
• Grantee: Ana Carolina Lourenço
• Host Institution: Faculdade de Medicina de Ribeirão Preto (FMRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil

Abstract

The use of proton pump inhibitors (PPIs) has been associated with an increased risk of developing cardiovascular disease. There is evidence that PPIs increases the activity of asymmetric dimethylarginine (ADMA), which is an endogenous inhibitor of nitric oxide (NO). Other studies indicates that omeprazole increases the activity of xanthine oxidoreductase (XOR), promoted by ADMA, causing greater formation of reactive oxygen species, which increases the activity of matrix metalloproteinase (MMPs), which are present in vascular remodeling and alterations in the structure of vessels. The hypothesis is that acute use of pantoprazole promotes endothelial dysfunction associated with increased oxidative stress and MMPs. The aim of the study is to evaluate the effects of pantoprazole treatment on biochemical parameters, endothelial function and blood pressure assessment in healthy volunteers. For the study, 20 healthy male volunteers will be recruited. After agreeing and signing the informed consent form, they will undergo physical and laboratory exams. If they meet the inclusion criteria, they will be randomized to one of groups of the study. The study will last for two months. It will start with blood and saliva collection, followed by functional tests. After that, participants will receive placebo and pantoprazole for 30 days and at the end we will collect blood, saliva and perform functional tests. For continuation of the study, the group receiving placebo will take pantoprazole and the group receiving pantoprazole will take placebo for 30 days. At the end of the treatment we will repeat the same tests and the study will be concluded.